Overview

Dexmedetomidine and Vasopressin in Septic Shock

Status:
NOT_YET_RECRUITING
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Rudiger and Singer suggested strategies for refining adrenergic stress (decatecholaminization). They proposed the use of dexmedetomidine and vasopressin to reduce the catecholamine load during sepsis. The investigators will use vasopressin as the primary vasopressor and a heart rate-calibrated dexmedetomidine infusion in septic shock patients. The investigators of the current study will use DEXPRESSIN in septic shock patients to investigate the effects of decatecholaminization on in-hospital mortality.
Phase:
PHASE2
Details
Lead Sponsor:
Mansoura University
Treatments:
Control Groups
Standard of Care